BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 22391104)

  • 1. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
    Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine.
    Cheney MD; Chen YL; Lim R; Winrich BK; Grosu AL; Trofimov AV; Depauw N; Shih HA; Schwab JH; Hornicek FJ; DeLaney TF
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1030-6. PubMed ID: 25539367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
    Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ
    Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
    Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
    Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
    Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
    Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
    Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
    Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
    Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
    Pinker K; Andrzejewski P; Baltzer P; Polanec SH; Sturdza A; Georg D; Helbich TH; Karanikas G; Grimm C; Polterauer S; Poetter R; Wadsak W; Mitterhauser M; Georg P
    PLoS One; 2016; 11(5):e0155333. PubMed ID: 27167829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
    Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
    Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.
    Tachibana I; Nishimura Y; Shibata T; Kanamori S; Nakamatsu K; Koike R; Nishikawa T; Ishikawa K; Tamura M; Hosono M
    J Radiat Res; 2013 Nov; 54(6):1078-84. PubMed ID: 23589026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
    Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
    Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
    Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M
    Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
    Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
    Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
    Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.